Corvus Pharmaceuticals, Inc.

CRVS · NASDAQ
Analyze with AI
9/30/2025
6/30/2025
3/31/2025
12/31/2024
Operating Activities
Net Income-$10,157-$7,998$15,193-$12,113
Dep. & Amort.$28$29$22$20
Deferred Tax$0$0$0$0
Stock-Based Comp.$0$1,256$1,251$845
Change in WC-$550$2,893$152-$1,459
Other Non-Cash$1,113-$1,957-$24,881$4,242
Operating Cash Flow-$9,566-$5,777-$8,263-$8,465
Investing Activities
PP&E Inv.$0-$113-$36$5
Net Acquisitions$0$0$0$0
Inv. Purchases-$31,149-$39,475-$7,708-$20,361
Inv. Sales/Matur.$28,531$19,287$11,987$14,273
Other Inv. Act.$0$0$0$0
Investing Cash Flow-$2,618-$20,301$4,243-$6,083
Financing Activities
Debt Repay.$0$0$0$0
Stock Issued$360$35,770$279$18,608
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$0$0$0$0
Financing Cash Flow$360$35,770$279$18,608
Forex Effect$0$0$0$0
Net Chg. in Cash-$11,824$9,692-$3,741$4,060
Supplemental Information
Beg. Cash$14,691$4,999$8,740$4,680
End Cash$2,867$14,691$4,999$8,740
Free Cash Flow-$9,566-$5,890-$8,299-$8,465